Dr. Rizo brings extensive industry leadership experience to Vividion, having held multiple senior executive roles during her career at both biotechnology and large pharmaceutical companies.
The company is strategically expanding its product portfolio with a pipeline of new products that will form a strong foundation for future growth.
Guindo will be responsible for leading the development and implementation of the company’s long-term strategy for the Human Health portfolio.
Ganguly will execute company's strategic focus on leveraging CustomGlycan to develop novel therapeutics
Large datasets will train machine learning models and speed up agile discovery of novel crop protection solutions
Bayer now present in four of the largest biotechnology hubs in the United States
Cloud-native Alissa data analysis SaaS platform empowers clinical labs and researchers to scale operations with parallel analysis of genomic data
Innate to receive $5M milestone payment from AstraZeneca
Follows Zealand Pharma’s appointment of Adam Steensberg as CEO and decision to refocus strategy
GSK to pay $2.1 billion upfront and up to $1.2 billion in potential development milestones
Subscribe To Our Newsletter & Stay Updated
